Validation of a Panel of Patient-Derived Xenograft Models for Prostate Cancer and Cell Line Models for Preclinical Drug Evaluation
Nektaria Papadopoulou, Jane Wrigley, Andrew McKenzie, Lucy Harris, Jason King, Louise Wainwright, Kelly Jones, Qian Shi, Anne Collins*, and Rajendra Kumari
*University of York, York, UK
Prostate cancer is the second most common cancer worldwide for males, and the fourth most common cancer overall, with more than a million new cases diagnosed annually.
Progress towards understanding prostate cancer biology and developing new therapies has been hampered by a lack of in vivo models that adequately represent the spectrum of benign, latent, aggressive, and metastatic forms of the disease.
Learn about the validation of a panel of preclinical prostate cancer models including cell line models and new patient-derived xenografts (PDX) designed to meet this need.
Read this Poster to Discover:
- The characterization of both cell line derived and new and unique patient-derived xenograft models of hormone sensitive and castration-resistant prostate cancer
- Subcutaneous models as well as orthotopic models to assess metastasis, including bioluminescent imaging
- How these models provide a clinically relevant platform spanning the many different stages of prostate cancer for preclinical drug evaluation